Kuitwaard, K.

patient treatment study trial demyelinating syndrome cidp patients level neurol disease demyelinating polyneuropathy neurology demyelinating polyradiculoneuropathy immunoglobulin effect guillain-barre syndrome score gbs patients ivig treatment polyneuropathy flammatory demyelinating polyradiculoneuropathy doorn outcome serum month van doorn pa guillain –barre syndrome guillain serum igg levels 2 weeks guillain-barre gbs disability score 6 months nerve kuitwaard disability guillain –barr syndrome improvement hughe ef ficacy ⌬ igg course randomized dosage fatigue infusion plasma exchange group schmitz pi flammatory scale igg levels phase diagnosis muscle cell transplantation netherland vaccination neurosurg range erasmus mc plasma brand pharmacokinetic increase cidp patient weakness quartile ivig dose response efficacy transplantation factor preparation therapy exchange psychiatry van koningsveld r kg body weight –barre